Featured Research

from universities, journals, and other organizations

Testing African couples for HIV is cost-effective prevention strategy

Date:
September 30, 2010
Source:
Emory University
Summary:
As researchers and policymakers work toward an effective HIV vaccine in a constrained global economy, cost-effective prevention strategies such as "Couples Voluntary Counseling and Testing" must take a larger role in efforts to decrease the rates of HIV/AIDS in Africa, experts urge.

As researchers and policymakers work toward an effective HIV vaccine in a constrained global economy, cost-effective prevention strategies such as Couples Voluntary Counseling and Testing (CVCT) must take a larger role in efforts to decrease the rates of HIV/AIDS in Africa, says Emory University HIV/AIDS vaccine researcher Susan Allen, MD, MPH.

Allen, who has worked to combat the AIDS epidemic in Africa for more than 25 years, highlighted the value of CVCT and other cost-effective HIV prevention strategies today at the AIDS Vaccine 2010 Conference in Atlanta.

"The majority of new HIV infections are acquired from a spouse, and couples are the largest HIV risk group in Africa," says Allen, a professor of pathology and laboratory medicine in the Emory School of Medicine and adjunct faculty member in the Rollins School of Public Health. "By using CVCT to identify those people who do not share the same HIV status as their spouse or partner, we're in a better place to move forward efficiently and effectively once a vaccine does become available."

Allen, founder of the Rwanda Zambia HIV Research Group (RZHRG), notes that the positive impact of CVCT has been supported by published evidence since the early 1990s, yet the program has not yet been implemented on a wide scale. Of more than 30 million Africans tested for HIV, less than one percent has been tested with their spouses, says Allen.

"Funding agencies are only now beginning to understand and appreciate the value of CVCT as part of a broader HIV/AIDS strategy," Allen says.

An estimated 23 million Africans are HIV positive, yet only 3 million are receiving antiretroviral treatment (ARVT). The World Health Organization calculates that for every two new ARVT patients, five new HIV infections occur.

The U.S. government spends approximately $2.2 billion -- 10 percent of the entire U.S. bilateral foreign assistance budget -- on antiretroviral treatment. Treating one ARVT patient for 10 years costs about $7,000. In comparison, providing couples with voluntary counseling and testing would prevent new HIV infections at a cost of about $300 each, and would leverage other vital programs such as family planning, Allen says.

"The population of Zambia, for example, has grown by more than 50 percent over the last 20 years, but the U.S. has only allocated about 1.3 percent of its budget for family planning. At the same time, more than 60 percent of these budgets have been earmarked for antiretroviral drugs and care, even though less than two percent of the population is on ARVT."

As the population steadily increases, Allen says, funding agencies will face even more pressure to use their funds wisely.

"CVCT is an economical, sustainable and proven model for reducing the rate of HIV/AIDS infections in Africa."


Story Source:

The above story is based on materials provided by Emory University. Note: Materials may be edited for content and length.


Cite This Page:

Emory University. "Testing African couples for HIV is cost-effective prevention strategy." ScienceDaily. ScienceDaily, 30 September 2010. <www.sciencedaily.com/releases/2010/09/100930143345.htm>.
Emory University. (2010, September 30). Testing African couples for HIV is cost-effective prevention strategy. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2010/09/100930143345.htm
Emory University. "Testing African couples for HIV is cost-effective prevention strategy." ScienceDaily. www.sciencedaily.com/releases/2010/09/100930143345.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins